Ranbaxy Pharmaceuticals is voluntarily recalling certain lots of its atorvastatin calcium tablets.

Sorin Group has made a minority investment with option-to-buy in HighLife, an early-stage company focused on the development of a transcatheter mitral valve replacement system to treat patients with mitral regurgitation.

Endovascular repair and open repair resulted in similar long-term survival, and the perioperative survival advantage with endovascular repair was sustained for several years. But rupture after repair remained a concern, according to the OVER Veterans Affairs Cooperative Study.

Morton Plant Mease Health Care and its affiliated hospitals, which serve two Tampa Bay counties in Florida, have agreed to pay more than $10 million to the federal government to resolve allegations that they improperly billed for interventional cardiac and vascular procedures.

The European Commission has approved apixaban for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk factors.

It is possible to predict the risk that a patient will develop stent thrombosis after PCI for treatment of acute coronary syndrome using an assessment tool that considers several readily available variables, according to a study published in the November issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.

A class action complaint was filed on Nov. 16 in the United States District Court for the District of Massachusetts by Karse Simon and Arlene Simon, on behalf of themselves and persons or entities that purchased or acquired Abiomed's securities between Aug. 5, 2011, and Oct. 31, 2012, against Abiomed, Michael R. Minogue, Abiomed's chairman, president and CEO, and Robert L. Bowen, Abiomed's chief financial officer.

The FDA found what it described as several inadequacies during an inspection of a St. Jude Medical facility in California. In a redacted report, the agency cited activities related to St. Jude’s Durata product.